{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for isavuconazonium in Reference Text / Citation (approximate match)
Showing 1 - 3 of 3 results
Status:
US Approved Rx
(2015)
Source:
NDA207500
(2015)
Source URL:
First approved in 2015
Source:
NDA207500
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cytoplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
Status:
US Approved Rx
(2015)
Source:
NDA207500
(2015)
Source URL:
First approved in 2015
Source:
NDA207500
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cytoplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
Status:
US Approved Rx
(2015)
Source:
NDA207500
(2015)
Source URL:
First approved in 2015
Source:
NDA207500
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Isavuconazole is an active form of isavuconazonium, a prodrug which is marketed under the name Cresemba. Isavuconazole inhibits lanosterol 14-alpha demethylase (or CYP51A1) and leads to the accumulation of ergosterol toxic precursors in the fungal cytoplasm. Isavuconazole is indicated for the treatment of invasive aspergillosis and invasive mucormycosis.
